PMID- 28115959 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 1689-832X (Print) IS - 2081-2841 (Electronic) IS - 2081-2841 (Linking) VI - 8 IP - 6 DP - 2016 Dec TI - Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy. PG - 525-532 LID - 10.5114/jcb.2016.64743 [doi] AB - PURPOSE: This study assessed the modeled probability of tumor control and organ at risk toxicities in locally advanced cervical cancer in patients treated by external beam radiation plus brachytherapy using intracavitary combined with interstitial brachytherapy (IC/IS) vs. intracavitary brachytherapy (IC) alone. MATERIAL AND METHODS: Twenty cervical cancer patients with a mean HR-CTV volume of 47.4 cm(3) and a mean width of 54 mm were planned with both IC/IS and IC brachytherapy alone. A probit model was utilized to model 3-year (3-yr) local control rate (LC), 3-yr cancer specific survival rate (CSS), and the adverse effect (AE) of the organ at risk by using a modeled data set from multiple institutions. Modeling results were used to estimate the LC, CSS, and AE of the treatments in this study. RESULTS: Using the IC/IS technique, an EQD(2) increase of 12.3 Gy to D(90) (from 76.1 Gy to 88.3 Gy) of HR-CTV is expected to increase 3-yr LC and 3-yr CSS by 12.5%, and 11.0%, respectively. Comparing IC/IS to IC alone, the expected G2(+) AE were 7.7% vs. 7.9% for the bladder, and 5.9% vs. 6.8% for the rectum. CONCLUSIONS: The IC/IS technique improved dose coverage to the HR-CTV without significantly increasing dose to 2 cm(3) of the organ at risk (OAR) surrounding it. With different regimens of EBRT combined with BT, IC/IS can be used to increase the probability of LC and CSS, or decrease the risk of AE. FAU - Kuo, Hsiang-Chi AU - Kuo HC AD - Department of Radiation Oncology, Montefiore Medical Center, New York; Albert Einstein College of Medicine, New York. FAU - Mehta, Keyur J AU - Mehta KJ AD - Department of Radiation Oncology, Montefiore Medical Center, New York; Albert Einstein College of Medicine, New York. FAU - Yaparpalvi, Ravindra AU - Yaparpalvi R AD - Department of Radiation Oncology, Montefiore Medical Center, New York; Albert Einstein College of Medicine, New York. FAU - Shankar, Viswanathan AU - Shankar V AD - Albert Einstein College of Medicine, New York; Department of Epidemiology and Population Health, New York, USA. FAU - Bodner, William AU - Bodner W AD - Department of Radiation Oncology, Montefiore Medical Center, New York; Albert Einstein College of Medicine, New York. FAU - Garg, Madhur AU - Garg M AD - Department of Radiation Oncology, Montefiore Medical Center, New York; Albert Einstein College of Medicine, New York. FAU - Rivera, Amanda AU - Rivera A AD - Department of Radiation Oncology, Montefiore Medical Center, New York. FAU - Tome, Wolfgang A AU - Tome WA AD - Department of Radiation Oncology, Montefiore Medical Center, New York; Albert Einstein College of Medicine, New York. FAU - Kalnicki, Shalom AU - Kalnicki S AD - Department of Radiation Oncology, Montefiore Medical Center, New York; Albert Einstein College of Medicine, New York. LA - eng PT - Journal Article DEP - 20161220 PL - Poland TA - J Contemp Brachytherapy JT - Journal of contemporary brachytherapy JID - 101506276 PMC - PMC5241380 OTO - NOTNLM OT - adverse effect OT - brachytherapy OT - cervical cancer OT - tumor control EDAT- 2017/01/25 06:00 MHDA- 2017/01/25 06:01 PMCR- 2016/12/01 CRDT- 2017/01/25 06:00 PHST- 2016/06/07 00:00 [received] PHST- 2016/11/24 00:00 [accepted] PHST- 2017/01/25 06:00 [entrez] PHST- 2017/01/25 06:00 [pubmed] PHST- 2017/01/25 06:01 [medline] PHST- 2016/12/01 00:00 [pmc-release] AID - 28945 [pii] AID - 10.5114/jcb.2016.64743 [doi] PST - ppublish SO - J Contemp Brachytherapy. 2016 Dec;8(6):525-532. doi: 10.5114/jcb.2016.64743. Epub 2016 Dec 20.